新型冠狀病毒肺炎是由嚴(yán)重急性呼吸道綜合征冠狀病毒2引起的急性呼吸道傳染病,是近百年來(lái)人類遭遇的影響范圍最廣的全球性大流行疾病。抗病毒藥物是治療新型冠狀病毒感染的首選?？诜》肿涌剐滦凸跔畈《舅幬锸褂梅奖?且適用于輕中癥患者。目前小分子抗新型冠狀病毒藥物有血管緊張素轉(zhuǎn)換酶2(ACE2)抑制劑、膜融合抑制劑、RNA聚合酶抑制劑和3CL蛋白酶抑制劑。歸納了口服小分子抗新型冠狀病毒藥物的研究進(jìn)展,為口服小分子抗新型冠狀病毒藥物的研發(fā)提供思路。

Coronavirus disease 2019 (COVID-19), which emerged in December 2019, is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection，which is the most widespread global pandemic in the past century. Antiviral drugs are the first choice for treatment of SARS-CoV-2 infection. Orally small molecule antiviral drugs against SARS-CoV-2 are convenient to use and suitable for patients with mild and moderate cases. At present, orally small molecule antiviral drugs against SARS-CoV-2 include ACE2 inhibitor, membrane fusion inhibitor, RNA polymerase inhibitor and 3CL protease inhibitor. This article focuses on research progress on orally small molecule antiviral drugs against SARS-CoV-2 to provide ideas for its drug development.

R978.7

河北省醫(yī)學(xué)科學(xué)研究課題計(jì)劃(20200034)